Literature DB >> 20425150

Darusentan in resistant hypertension: lost in translation.

Frank Enseleit1, Frank Ruschitzka.   

Abstract

Entities:  

Year:  2010        PMID： 20425150     DOI： 10.1007/s11906-009-0081-y

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  12 in total

1.  [Plasma endothelin in normal probands and patients with nephrologic-rheumatologic and cardiovascular diseases].

Authors:  J Schrader; U Tebbe; M Borries; F Ruschitzka; G Schoel; M Kandt; G Warneke; C Züchner; M H Weber; U Neu
Journal:  Klin Wochenschr       Date:  1990-08-02

2.  Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).

Authors:  Thomas F Lüscher; Frank Enseleit; Richard Pacher; Veselin Mitrovic; Matthias R Schulze; Roland Willenbrock; Rainer Dietz; Valentin Rousson; David Hürlimann; Sebastian Philipp; Thomas Notter; Georg Noll; Frank Ruschitzka
Journal:  Circulation       Date:  2002-11-19       Impact factor: 29.690

3.  Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators.

Authors:  L E Spieker; V Mitrovic; G Noll; R Pacher; M R Schulze; J Muntwyler; C Schalcher; W Kiowski; T F Lüscher
Journal:  J Am Coll Cardiol       Date:  2000-06       Impact factor: 24.094

4.  The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.

Authors:  H Krum; R J Viskoper; Y Lacourciere; M Budde; V Charlon
Journal:  N Engl J Med       Date:  1998-03-19       Impact factor: 91.245

5.  Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.

Authors:  Inder Anand; John McMurray; Jay N Cohn; Marvin A Konstam; Thomas Notter; Kurt Quitzau; Frank Ruschitzka; Thomas F Lüscher
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

Review 6.  The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

Authors:  N S Kirkby; P W F Hadoke; A J Bagnall; D J Webb
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

Review 7.  Darusentan: a new perspective for treatment of resistant hypertension?

Authors:  Frank Enseleit; Thomas F Lüscher; Frank Ruschitzka
Journal:  Expert Opin Investig Drugs       Date:  2008-08       Impact factor: 6.206

8.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A J Struijker Boudier; Alberto Zanchetti; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Gerasimos Filippatos; Christian Funck-Brentano; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; Jose Luis Zamorano; Sverre E Kjeldsen; Serap Erdine; Krzysztof Narkiewicz; Wolfgang Kiowski; Enrico Agabiti-Rosei; Ettore Ambrosioni; Renata Cifkova; Anna Dominiczak; Robert Fagard; Anthony M Heagerty; Stephane Laurent; Lars H Lindholm; Giuseppe Mancia; Athanasios Manolis; Peter M Nilsson; Josep Redon; Roland E Schmieder; Harry A J Struijker-Boudier; Margus Viigimaa; Gerasimos Filippatos; Stamatis Adamopoulos; Enrico Agabiti-Rosei; Ettore Ambrosioni; Vicente Bertomeu; Denis Clement; Serap Erdine; Csaba Farsang; Dan Gaita; Wolfgang Kiowski; Gregory Lip; Jean-Michel Mallion; Athanasios J Manolis; Peter M Nilsson; Eoin O'Brien; Piotr Ponikowski; Josep Redon; Frank Ruschitzka; Juan Tamargo; Pieter van Zwieten; Margus Viigimaa; Bernard Waeber; Bryan Williams; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2007-06-11       Impact factor: 29.983

9.  Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension.

Authors:  Roumen Nakov; Egon Pfarr; Siegfried Eberle
Journal:  Am J Hypertens       Date:  2002-07       Impact factor: 2.689

10.  Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.

Authors:  Henry R Black; George L Bakris; Michael A Weber; Robert Weiss; Mahfouz El Shahawy; Richard Marple; Georges Tannoury; Stuart Linas; Brian L Wiens; Jennifer V Linseman; Robert Roden; Michael J Gerber
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-10       Impact factor: 3.738
View more
  1 in total

1.  Controlling Hypertension: We Have the Tools-We Just Need to Use Them.

Authors:  David J Hyman; Valory Pavlik
Journal:  J Gen Intern Med       Date:  2017-08       Impact factor: 5.128
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.